medigraphic.com
SPANISH

Acta Médica Grupo Ángeles

ISSN 3061-7774 (Electronic)
ISSN 1870-7203 (Print)
Órgano Oficial del Hospital Ángeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Manuscript submission
    • Policies
    • Names and affiliations of the Editorial Board
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2026, Number 3

<< Back Next >>

Acta Med 2026; 24 (3)

Analysis of antimicrobial resistance in bacterial infections at the Central Hospital of the State of Chihuahua

Jáuregui BRI, Molina CG, Pérez RMD, Nieto DJ
Full text How to cite this article 10.35366/123138

DOI

DOI: 10.35366/123138
URL: https://dx.doi.org/10.35366/123138

Language: Spanish
References: 22
Page: 207-214
PDF size: 688.29 Kb.


Key words:

targeted therapy, antimicrobial resistance, extended resistance, multidrug resistance, healthcare-associated infection.

ABSTRACT

Introduction: antimicrobial resistance is a major challenge in the management of infections associated with health care. Objective: determine the patterns of antimicrobial resistance in bacterial infections at the Central Hospital of the State of Chihuahua. Material and methods: a non-experimental, descriptive, analytical study was conducted, as well as the study design is observational, cross-sectional and retrospective. 328 bacterial isolates were collected from the last two years from patients hospitalized at the Central Hospital of the State of Chihuahua. Results: it was generated through standard microbiological identification methods and antimicrobial sensitivity testing. Identifying high rates for third-generation cephalosporins, carbapenems and aminoglycosides. The most affected areas are the ICU and surgical areas. The most prevalent HAIs were VAP. Conclusions: the conclusions include the design of hospital guidelines adapted to the actual epidemiological evidence of the hospital center under study.


REFERENCES

  1. Aiesh BM, Nazzal MA, Abdelhaq AI, Abutaha SA, Zyoud SH, Sabateen A. Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics. Sci Rep. 2023; 13 (1): 5040. doi:10.1038/s41598-023-32329-6.

  2. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018; 11: 1645-1658. doi: 10.2147/IDR.S173867.

  3. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017; 6: 47. doi: 10.1186/s13756-017-0208-x.

  4. Camacho Silvas LA. Resistencia bacteriana, una crisis actual. Rev Esp Salud Publica. 2023; 97: e202302013.

  5. Secretaría de Salud. Guía para la vigilancia por laboratorio de la resistencia a los antimicrobianos [Internet]. Ciudad de México: Secretaría de Salud; 2022. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/943601/Gu_a_para_la_Vigilancia_por_Laboratorio_de_la_Resistencia_a_los_Antimicrobianos.pdf

  6. Hernández A, Yagüe G, García Vázquez E, Simón M, Moreno Parrado L, Canteras M et al. Infecciones nosocomiales por Pseudomonas aeruginosa multirresistente incluido carbapenémicos: factores predictivos y pronósticos. Estudio prospectivo 2016-2017. Rev Esp Quimioter. 2018; 31 (2): 123-130.

  7. Jiménez Pearson MA, Galas M, Corso A, Hormazábal JC, Duarte Valderrama C, Salgado Marcano N et al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes. Rev Panam Salud Publica. 2019; 43: e65. doi: 10.26633/RPSP.2019.65.

  8. Lepe JA, Martínez-Martínez L. Puesta al día en medicina intensiva: infecciones graves por gramnegativos multirresistentes. Mecanismos de resistencia en bacterias gramnegativas. Med Intensiva. 2022; 46 (1): 1-9. doi: 10.1016/j.medin.2022.02.004.

  9. Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos Trans R Soc Lond B Biol Sci. 2015; 370 (1670): 20140082. doi: 10.1098/rstb.2014.0082.

  10. Organización Mundial de la Salud. Lista de patógenos bacterianos prioritarios de la OMS, 2024: patógenos bacterianos de importancia para la salud pública para guiar la investigación, el desarrollo y las estrategias para prevenir y controlar la resistencia a los antimicrobianos [Internet]. Ginebra: OMS; 2024. Disponible en: https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1

  11. EClinicalMedicine. Antimicrobial resistance: a top ten global public health threat. EClinicalMedicine. 2021; 41: 101221. doi: 10.1016/j.eclinm.2021.101221.

  12. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2021; 399 (10325): 629-655. doi: 10.1016/S0140-6736(21)02724-0.

  13. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmacol. 2023; 16 (11): 1615. doi: 10.3390/ph16111615.

  14. Pérez-Torres D, Tamayo-Lomas LM, Domínguez-Gil González M, Almendros-Muñoz R, Sacristán-Salgado MA, González-González E et al. Programa de optimización del uso de antimicrobianos en un Servicio de Medicina Intensiva: análisis retrospectivo observacional de los resultados 15 meses después de su implementación. Rev Esp Quimioter. 2023; 36 (5): 477-485. doi: 10.37201/req/142.2022.

  15. Osorio G, Fresco L, Monclús E, Carbó M, Ortega M. Adecuación del uso de antibióticos de "Categoría Especial" en el Servicio de Urgencias de un hospital de tercer nivel. Rev Esp Quimioter. 2020; 33 (1): 24-31. doi: 10.37201/req/066.2019.

  16. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47 (11): 1181-1247. doi: 10.1007/s00134-021-06506-y.

  17. Smith J, Johnson L, Martinez R. Antimicrobial stewardship programs and the reduction of antimicrobial resistance: A review of current evidence. J Antimicrob Chemother. 2022; 77 (5): 1123-1130.

  18. Brown A, Davis M, Wilson T. Guidelines for the treatment of antimicrobial-resistant infections in adults. Clin Infect Dis. 2021; 73 (8): e262-e278.

  19. Wang X, Zhang Y, Liu T. Surveillance and reporting of antimicrobial resistance: a global perspective. J Glob Health. 2021; 11 (2): 02003.

  20. Moreno LI, Garza-González E. Active surveillance of antimicrobial resistance and carbapenemase-encoding genes according to sites of care and age groups in Mexico: results from the INVIFAR Network. Pathogens. 2023; 12 (9): 1144. doi: 10.3390/pathogens12091144.

  21. Consejo de Salubridad General. Acuerdo por el que se declara la obligatoriedad de la Estrategia Nacional de Acción contra la Resistencia a los Antimicrobianos [Internet]. Diario Oficial de la Federación; 5 de junio de 2018 [citado 24 de marzo de 2025]. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5525043&fecha=05/06/2018#gsc.tab=0

  22. Plan Universitario de Control de la Resistencia Antimicrobiana (PUCRA), Universidad Nacional Autónoma de México. Recomendaciones para el control de la resistencia antimicrobiana en México [Internet]. Ciudad de México: UNAM; 2019 [citado 24 de marzo de 2025]. Disponible en: http://www.puis.unam.mx/ReportePUCRArecomendaciones.pdf




Figure 1
Figure 2
Figure 3
Figure 4
Table 1

2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2026;24